Balancing access to opioid substitution treatment (OST) with preventing the diversion of opioid substitution medications in Europe: challenges and implications

Published By Europa [English], Wed, Feb 10, 2021 8:55 AM


This report reviews how opioid substitution treatment (OST) is implemented in European countries and examines the public health consequences of the diversion and misuse of prescription OST medications. It looks at how OST medications are diverted to the illicit market, the motivations behind diversion and misuse, and considers the measures to prevent diversion and how they must ensure that the treatment remains available and accessible for those who need it.

Press release distributed by Media Pigeon on behalf of Europa, on Feb 10, 2021. For more information subscribe and follow


Eric Mamer

Chief Spokesperson
[email protected]
+32 2 299 40 73

Dana Spinant

Deputy Chief Spokesperson
[email protected]
+32 2 299 01 50

Elisaveta Dimitrova

Head of Unit
[email protected]
+32 2 295 88 38

Johannes Bahrke

Coordinating Spokesperson
[email protected]
+32 2 295 86 15

Vivian Loonela

Coordinating Spokesperson
[email protected]
+32 2 296 67 12